Business
Locus Biosciences Enters Research Collaboration to Develop Precision Antibacterial Therapies for Ophthalmic Infections
RESEARCH TRIANGLE PARK, N.C., October 28, 2025--Locus Biosciences announced a research collaboration with Viatris to develop engineered bacteriophage therapies for ophthalmic infections.
About this update from Viatris Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":603,"height":229,"url":"https://media.zenfs.com/en/business-wire.com/c211a7dce37dc88ee34fbdfe973c25eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1v3CUSlIdI5WI39iJXzNYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM2NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c211a7dce37dc88ee34fbdfe973c25eb","width":603,"height":229}},"lazy":false},{"type":"text","content":"Collaboration to develop engineered bacteriophage therapeutics targeting bacterial pathogens responsible for serious eye infections","length":131,"tagName":"p","attribs":{}},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., October 28, 2025--(BUSINESS WIRE)--Locus Biosciences, Inc. ("Locus"), a clinical-stage biotechnology company developing precision engineered bacteriophage treatments for a diverse set of bacterial diseases, today announced a research collaboration agreement with Viatris Inc. (NASDAQ: VTRS), a global healthcare company, to develop novel engineered bacteriophage products targeting ophthalmic bacterial infections.","length":454,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Locus and Viatris will collaborate to develop precision antibacterial therapeutics for serious eye infections, an area of high unmet medical need due to the rise in antibiotic-resistant infections worldwide.","length":241,"tagName":"p"},{"type":"text","content":"Locus’s proprietary development platform integrates predictive artificial intelligence (AI), high-throughput robotics, and synthetic biology to create bacteriophage cocktails that selectively eliminate pathogenic bacteria while sparing beneficial species.","length":255,"tagName":"p"},{"type":"text","content":""This partnership with Viatris marks a significant milestone for Locus as we bring our world-leading bacteriophage therapy platform to ophthalmology," said Paul Garofolo, Co-founder and CEO of Locus Biosciences. "Targeted therapies are urgently needed to address the growing burden of antimicrobial resistance in eye infections. We’re proud to work with Viatris to accelerate the development of new precision medicines for patients in need."","length":461,"tagName":"p"},{"type":"text","content":"This collaboration underscore...